BACKGROUND: In the course of the influenza A H1N1 pandemic, transplanted @entity1 were recommended to receive vaccination. In the present study, we evaluated the immune response to an adjuvanted influenza A H1N1 vaccine ( @entity69919  ) in renal allograft recipients. METHODS: Sixty @entity1 and 22 healthy controls participated in a prospective observational study and received a single dose of @entity69919  . H1N1 antibody titres as well as anti-HLA antibodies were determined before and after vaccination. In 19 @entity1 , a booster vaccination was performed and the outcome of all vaccinated renal allograft recipients (n = 107) in our clinic was reviewed. RESULTS: Two out of sixty @entity1 had an elevated influenza A H1N1 titre before vaccination. Of the remaining 58 @entity1 , only 20/58 (34.5%) developed a protective immune response in contrast to 20/22 (91%) of the control group. After booster vaccination, a protective titre was present in 8/19 (42%) of @entity1 . Of the 107 @entity1 , 6 (5.6%) developed new donor-specific HLA antibodies after vaccination. CONCLUSIONS: These data suggest that @entity69919   does not provide a protective immune response in the majority of kidney transplant recipients. Therefore, for new vaccines, efficacy as well as safety profiles should be evaluated in this subgroup of @entity1 .

Immune response to an adjuvanted influenza A H1N1 vaccine ( XXXX (  )) in renal transplant recipients.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity69919 :: ('MESH:C556153', 'Chemical') :: ['Pandemrix']
@entity69919 :: (MESH:C556153,Chemical) :: ['Pandemrix']
